Bodal Chemicals reports strong Q2 & H1 FY26 results, approves sale of inoperative Unit-II
Bodal Chemicals announced strong Q2 & H1 FY26 consolidated and standalone results, moving from loss to profit. The board also approved the sale of an inoperative unit in Ahmedabad.
The strong financial performance, especially the shift from consolidated losses to profits, indicates a significant improvement in the company's operational efficiency and market position. The asset sale, while not revenue-significant, reflects proactive management decisions.
The company reported a significant turnaround from a consolidated loss to a profit and substantial growth in standalone profits for both the quarter and half year. The strategic decision to sell an inoperative asset is also a positive step towards optimizing operations and balance sheet.
* Bodal Chemicals Limited's Board of Directors met on November 12, 2025, to approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025. * Consolidated Financial Highlights (Q2 FY26 vs Q2 FY25): * Revenue from operations increased to ₹4,804.52 million from ₹4,321.23 million. * Profit for the period attributable to owners improved significantly to ₹59.93 million compared to a loss of ₹2.42 million in the prior year. * Basic Earnings Per Share (EPS) rose to ₹0.47 from a loss of ₹0.02. * Consolidated Financial Highlights (H1 FY26 vs H1 FY25): * Revenue from operations increased to ₹9,346.55 million from ₹8,540.85 million. * Profit for the period attributable to owners improved significantly to ₹155.26 million compared to a loss of ₹14.17 million in the prior year. * Basic EPS rose to ₹1.23 from a loss of ₹0.11. * Standalone Financial Highlights (Q2 FY26 vs Q2 FY25): * Revenue from operations increased to ₹4,719.55 million from ₹4,262.09 million. * Profit for the period increased to ₹41.97 million from ₹1.96 million. * Basic EPS rose to ₹0.33 from ₹0.05. * Standalone Financial Highlights (H1 FY26 vs H1 FY25): * Revenue from operations increased to ₹9,168.02 million from ₹8,464.10 million. * Profit for the period increased to ₹140.74 million from ₹17.27 million. * Basic EPS rose to ₹1.15 from ₹0.14. * The Board approved the sale of Unit – II located at Plot No: 123-124, Phase-I, G.I.D.C., Vatva, Ahmedabad. This unit was inoperative for a long time and was not a significant contributor to the company's revenue. * The company previously intimated the closure of Unit-II B and Unit-III on May 24, 2024. Profits from the sale of part of Unit-II (₹106.60 million) and Unit-III (₹72.34 million) are included in Other Income for the quarter ended September 30, 2025. * Regarding a fire incident in December 2024 at Unit 7, the company received an insurance claim of ₹47.11 million against a total claim of ₹59.91 million. The remaining loss of ₹0.30 million was booked as an Exceptional Item in the current quarter, with the claim now fully settled. * The company applied Ind AS 29 for its Turkish subsidiaries, with a net impact of ₹18.89 million debited for the quarter and ₹33.34 million for the half year ended September 30, 2025.
What to do with a filing like this
Bodal Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bodal Chemicals Limited. Read the original for the full detail.